Browse Peptide Current coverage filtered by experimental evidence framing.
29 articles
TB-500's timing depends on one crucial distinction: the marketed fragment differs from the full thymosin beta-4 in human trials. Here's what the research shows—and why that separation changes everything for your protocol.
Pinealon dosage clarity starts with one decision: route first. The public evidence points to older oral-use patterns and newer mechanistic research—here's how to build real protocol confidence.
You can stop guessing at BPC-157 dosage. Real answers live in the current trials and published data—but route matters more than any single number. Here's the practical breakdown.
Epitalon dosing clarity comes from understanding what the real human routines show—short courses, route-specific protocols, and why one settled U.S. standard still doesn't exist.
The AOD-9604 dosage question is clearest when you stick to clinical evidence: once-daily oral regimens in real human trials, followed by a larger study that changed everything. Here's what actually moved the needle.
Tirzepatide is the settled, approved option you can start using today. Retatrutide shows bigger weight-loss potential but remains investigational. Your pick depends on whether you want certainty now or the highest ceiling later.
Pinealon offers a genuinely different approach to cognition: restorative and neuroprotective, calmer than typical nootropics. The research is real and the mechanism is solid.
Master GHK-Cu dosage by treating topical and injectable as two different games. Topicals win on concentration and routine fit; injectables face tighter scrutiny. Route first, always.
Both peptides raise growth hormone through different signals and vastly different evidence histories. Sermorelin has authentic medical grounding; ipamorelin has a cleaner selectivity story but a much thinner human record.
FDA has set a July 23, 2026 compounding committee review for BPC-157, TB-500, and KPV, giving these recovery peptides a concrete U.S. regulatory date. It is not approval, but it is a real access milestone.
MOTS-c has finally entered human efficacy testing in the exact metabolic scenario that drove years of interest. A recruiting Phase 2a trial means the peptide's metabolism story is now being proven in real people, not just lab research.
BPC-157 draws recovery interest because the upside sounds genuinely practical: tissue repair, muscle recovery, gut support. The straight answer: genuine early signals, an active Phase 2 trial, and still-emerging human evidence.